Common Contracts
14 similar Employment Agreement contracts by Absci Corp, Centessa Pharmaceuticals PLC, Black Diamond Therapeutics, Inc., others
Employment AgreementEmployment Agreement • November 14th, 2023 • Absci Corp • Services-commercial physical & biological research • Washington
This Employment Agreement (“Agreement”) is made between Absci Corporation, a Delaware corporation (the “Company”), and Zachariah Jonasson (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 9th, 2023 • Black Diamond Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and Fang Z. Ni, Pharm.D. (the “Executive”) and is effective as of August 3, 2020 (the “Effective Date”). Except with respect to the Equity Documents (as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the offer letter between the Executive and the Company dated July 15, 2020 (the “Prior Agreement”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 9th, 2023 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Cullinan Management, Inc., a Delaware corporation (the “Company”), and Jeff Trigilio (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 10 below, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated August 25, 2020 (the “Prior Agreement”), and (ii) any offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2022 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”) is made by and between Centessa Pharmaceuticals, Inc. (the “U.S. Subsidiary”), a wholly owned subsidiary of Centessa Pharmaceuticals plc (“Parent”, with Parent, the U.S. Subsidiary and their respective subsidiaries and other affiliates referred to herein as the “Company”) and Saurabh Saha (the “Executive”) and is effective as of March 30, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment offer letter between the Executive and the Company dated as of November 19, 2020, revised on December 2, 2020 (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2022 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • Delaware
This Employment Agreement (this “Agreement”) is made by and between Centessa Pharmaceuticals, Inc. (the “U.S. Subsidiaries”), a wholly owned subsidiary of Centessa Pharmaceuticals plc (“Parent”, with Parent, the US Subsidiary and their respective subsidiaries and other affiliates referred to herein as the “Company”) and Gregory M. Weinhoff (the “Executive”) and is effective as of March 30, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment offer letter between the Executive and the Company dated as of February 27, 2021 (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2022 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • Delaware
This Employment Agreement (this “Agreement”) is made by and between Centessa Pharmaceuticals, Inc. (the “U.S. Subsidiary”), a wholly owned subsidiary of Centessa Pharmaceuticals plc (“Parent”, with Parent, the U.S. Subsidiary and their respective subsidiaries and other affiliates referred to herein as the “Company”) and Marella Thorell (the “Executive”) and is effective as of March 30, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the employment offer letter between the Executive and the Company dated as of December 8, 2020, revised on December 11, 2020 (the “Prior Agreement”) and (ii) any other offer letter, employment agreement or severance agreement.
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • March 29th, 2022 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and Philip Nickson, JD, Ph.D. (the “Executive”) and is effective as of March 1, 2022 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 22nd, 2022 • Absci Corp • Services-commercial physical & biological research • Washington
This Employment Agreement (“Agreement”) is made between Absci Corporation, a Delaware corporation (the “Company”), and Nikhil Goel (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the offer letter between the Executive and the Company dated May 28, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • March 22nd, 2022 • Absci Corp • Services-commercial physical & biological research • Washington
This Employment Agreement (“Agreement”) is made between Absci Corporation, a Delaware corporation (the “Company”), and Sarah Korman (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the offer letter between the Executive and the Company dated May 24, 2021 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • February 9th, 2022 • Brightcove Inc • Services-computer processing & data preparation • Delaware
This Employment Agreement (“Agreement”) is made as of the 8th day of February, 2022, between Brightcove Inc., a Delaware corporation (the “Company”), and Marc DeBevoise (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 15th, 2021 • Absci Corp • Services-commercial physical & biological research • Washington
This Employment Agreement (“Agreement”) is made between Absci Corporation, a Delaware corporation (the “Company”), and Gregory Huffman (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the offer letter between the Executive and the Company dated March 26, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • July 15th, 2021 • Absci Corp • Services-commercial physical & biological research • Washington
This Employment Agreement (“Agreement”) is made between Absci Corporation, a Delaware corporation (the “Company”), and Sean McClain (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Equity Documents (as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • July 15th, 2021 • Absci Corp • Services-commercial physical & biological research • Washington
This Employment Agreement (“Agreement”) is made between Absci Corporation, a Delaware corporation (the “Company”), and Andreas Pihl (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below) and subject to Section 11, this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • June 15th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (the “Agreement”) is made between FORMA Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Change in Control and Severance Agreement between the Executive and the Company dated (the “Prior Agreement”), and (ii) any offer letter, employment agreement or severance agreement.
